Start
Features
Free trial / FAQ

Researchers
Physicians
Pharmacists
Ecotrophologists
Product Managers
in Health Industries

Loading…

Medical Research Finder

Legal Notice
Privacy
Terms of Use

meRfi® Microbiome - The Digital Gut Microbiome Reference (incl. AI Chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

meRfi® AI Chat

Bifidobacterium animalis lactis + Fructooligosaccharides (FOS) & Non-Alcoholic Fatty Liver Disease (NAFLD) / Metabolic dysfunction-associated fatty liver disease (MAFLD)

Welcome to meRfi Microbiome!

Please register to continue your trial period!

meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

(Login)

Navigation

Clinical data

NCT01680640 - Bifidobacterium animalis lactis BB-12 + Fructooligosaccharides (FOS) & Non-Alcoholic Fatty Liver Disease (NAFLD) / Metabolic dysfunction-associated fatty liver disease (MAFLD)

This randomized clinical phase II treatment trial revealed that the synbiotic treatment successfully altered the gut microbiota; however, this combination of pro- and prebiotics did not effectively improve liver fat content or liver fibrosis markers in individuals with NAFLD.
Scorletti et al. 2020 Gastroenterology 158(6): 1597-1610

…

References (Sources)

Synbiotics Alter Fecal Microbiomes, But Not Liver Fat or Fibrosis, in a Randomized Trial of Patients With Nonalcoholic Fatty Liver Disease
Scorletti et al. 2020 Gastroenterology 158(6): 1597-1610

AI Chat

7/1/2026

Chat with our artificial intelligence:

Start chat!